+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


A-Share Listed Biological Products Companies - Profiles and Financial Data

  • ID: 4116685
  • Report
  • March 2017
  • Region: China
  • 160 pages
  • China Research & Intelligence
In China, biological products include: bacterial vaccines (containing toxoid), viral vaccines, antitoxin and antiserum, blood products, cytokine, growth factors, enzyme, in vivo and in vitro diagnostic products, and other biological active preparations.

According to this report, fast economic growth and residents' increasing income have pushed up people's medical expenses. China's biological products market outperforms the global average. In China, the market size exceeded CNY 130 billion in 2016, but its share in the pharmaceutical market was less than 10%, far below that in developed countries.

In the Thirteenth Five-Year Plan (2016-2020), biotechnological pharmaceuticals, new vaccines, new cell therapy preparations and other innovative pharmaceuticals were listed among the priorities of the biomedicine industry. It is expected that in the next few years, biotechnological advances and favorable policies will facilitate fast growth of the biological product industry.

In this report, 38 biological products manufacturers listed in A-share market in China are analyzed.

The report is composed of two parts: the first part is enterprise profiles and the second part is the operation status of these enterprises in the recent decade (presently 2006 to 2016, we will update it to the latest as time goes by).

The operation status is demonstrated from the following perspectives: (1)financial indexes, such as earnings per share, book value per share (BPS), sales per share, net cash flow per share, return on net worth and debt to asset ratio; (2) indexes on the income statement, such as revenue, operating profit, net profit and EBIT; (3) indexes on the income statement, such as revenue, operating profit, net profit and EBIT; (4) indexes on the balance sheet, such as liquid asset, fixed asset, current liability, non-current liability, capital reserve and shareholders' equity.
Note: Product cover images may vary from those shown
1. Financial Indexes
- Earnings per Share
- Book Value per Share (BPS)
- Sales per Share (SPS)
- Net Cash Flow per Share from Operations
- Net Cash Flow per Share (CNY)
- Return on Net Worth
- Net Profit Margin on Total Assets
- Return on Invested Capital (ROIC) (%)
- Gross Profit Margin on Sales (%)
- Net Profit Margin on Sales (%)
- EBIT Margin (%)
- EBITDA Margin (%)
- Debt to Asset Ratio (%)
- Total Asset Turnover (times)
- Cash/Operating Income Received from Sales of Goods or Services
- YOY Growth Rate of Operating Revenue (%)
- YOY Growth Rate of Operating Profit (%)
- YOY Growth Rate of Net Profit Attributable to Shareholders of Parent Company (%)

2. Summary of Income Statement
- Gross Revenue (CNY, million)
- Total Operating Costs (CNY, million)
- Revenue (CNY, million)
- Operating Profit (CNY, million)
- Total Profit (CNY, million)
- Net Profit (CNY, million)
- Net Profit Attributable to Shareholders of Parent Company (CNY, million)
- Non-recurring Items (CNY, million)
- Net Profit Deducting Non-recurring Items (CNY, million)
- R&D Costs (CNY, million)
- Earnings Before Interest and Tax (EBIT) (CNY, million)
- Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (CNY, million)

3. Summary of Balance Sheet
- Liquid Asset (CNY, million)
- Fixed Asset (CNY, million)
- Long-term Equity Investment
- Total Assets (CNY, million)
- Liquid Liability (CNY, million)
- Non-current Liability (CNY, million)
- Total Liability (CNY, million)
- Capital Reserve (CNY, million)
- Surplus Reserve (CNY, million)
- Undistributed Profit (CNY, million)
- Shareholders' Equity (CNY, million)
- Equity Attributable to Shareholders of Parent Company (CNY, million)

4. Summary of Cash Flow Statement
- Cash Received from Sales of Goods and Services (CNY, million)
- Cash Flow from Operations (CNY, million)
- Cash Paid to Purchase Fixed Assets, Intangible Assets and Other Long-term Assets (CNY, million)
- Cash Paid for Investments (CNY, million)
- Cash Flow from Investments (CNY, million)
- Cash Received from Investors (CNY, million)
- Cash Received from Borrowings (CNY, million)
- Cash Flow from Financing (CNY, million)
- Net Increase of Cash and Cash Equivalents (CNY, million)
- Cash and Cash Equivalents, End of Period (CNY, million)
- Depreciation and Amortization (CNY, million)
Note: Product cover images may vary from those shown
  • Ginwa Enterprise (Group) Inc. (600080.SH)
  • Beijing Tiantan Biological Products Co., Ltd. (600161.SH)
  • Shanghai Fosun Pharmaceutical Co., Ltd. (600196.SH)
  • Bluestar Adisseo Company (600299.SH)
  • Shanghai Jiaoda Onlly Co., Ltd. (600530.SH)
  • Zhongyuan Union Cell & Gene Engineering Corp., Ltd. (600645.SH)
  • Zhejiang Qianjiang Biochemical Co., Ltd. (600796.SH)
  • Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SH)
  • Autobio Diagnostics Co., Ltd. (603658.SH)
  • Wuhan Thalys Medical Technology Inc. (603716.SH)
  • Shenzhen Cau Technology Co., Ltd. (000004.SZ)
  • Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ)
  • Zhenxing Biopharmaceutical & Chemical Inc. (000403.SZ)
  • Jiangsu Sihuan Bioengineering Co., Ltd. (000518.SZ)
  • Changchun High-Tech Industry Co., Ltd. (000661.SZ)
  • Hualan Biological Engineering Co., Ltd. (002007.SZ)
  • Shanghai Kehua Bio-engineering Co., Ltd. (002022.SZ)
  • DAAN Gene Co., Ltd. of Sun Yat-sen University (002030.SZ)
  • Beijing SL Pharmaceutical Co., Ltd. (002038.SZ)
  • Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
  • Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ)
  • Changsheng Bio-technology Co., Ltd. (002680.SZ)
  • Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ)
  • Chongqing Chifei Biological Products Co., Ltd. (300122.SZ)
  • Walvax Biotechnology Co., Ltd. (300142.SZ)
  • Staidson (Beijing) Biopharmaceuticals Co., Ltd. (300204.SZ)
  • Baotou Dongbao Bio-Tech Co., Ltd. (300239.SZ)
  • Beijing Leadman Biochemistry Co., Ltd. (300289.SZ)
  • Jiangxi Boya Bio-pharmaceutical Co., Ltd. (300294.SZ)
  • Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
  • Guangdong Vtr Bio-Tech Co., Ltd. (300381.SZ)
  • Beijing Strong Biotechnologies, Inc. (300406.SZ)
  • Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ)
  • Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
  • Sichuan Maccura Biotechnology Co., Ltd. (300463.SZ)
  • Guangzhou Wondfo Biotech Co., Ltd. (300482.SZ)
  • Shandong Sito Bio-technology Co., Ltd. (300583.SZ)
  • Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ)
Note: Product cover images may vary from those shown

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.